Related Experiment Video
Updated: Mar 7, 2026

10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
16.4K
Technologies Assessing Limb Bradykinesia in Parkinson's Disease
Hasan Hasan1, Dilan S Athauda1,2, Thomas Foltynie1,2
1UCL Institute of Neurology, Queen Square, London, UK.
Journal of Parkinson'S Disease
|February 23, 2017
Summary
Novel technologies can objectively measure limb bradykinesia in Parkinson's disease (PD), overcoming limitations of the Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). This review synthesizes available tools for improved PD assessment.
Area of Science:
- Neurology
- Biomedical Engineering
- Rehabilitation Technology
Background:
- Parkinson's disease (PD) assessment relies on the Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
- Bradykinesia subscores within the MDS-UPDRS exhibit low reliability due to rater variability.
- Technological innovations offer potential solutions for objective motor impairment measurement in PD.
Purpose of the Study:
- To systematically review and describe technologies for measuring limb bradykinesia in Parkinson's disease.
- To cover technologies published between 2006 and 2016.
Main Methods:
- A comprehensive literature search was conducted across major scientific databases (PubMed, IEEE Xplore, Web of Science, Scopus, Engineering Village).
- The search identified technologies assessing limb bradykinesia in PD up to October 18, 2016.
Main Results:
- 47 distinct technologies for assessing PD bradykinesia were identified.
- 17 technologies supported both home and clinic-based assessments, while 30 were clinic-based only.
- Most technologies (40/47) were validated in both PD patients and healthy controls; 28 assessed bradykinesia alongside other parkinsonian features.
Conclusions:
- Technology-based tools provide objective motor assessment and enable home monitoring of PD symptoms.
- These tools can enhance the evaluation of intervention responses in clinical trials and routine care.
- This review serves as a repository of current technologies and discusses future trends in PD assessment technology.
Related Concept Videos
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

